STOCK TITAN

Valneva Se SEC Filings

VALN Nasdaq

Welcome to our dedicated page for Valneva Se SEC filings (Ticker: VALN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

Valneva SE is a French biotech company headquartered in Saint-Herblain, France, developing and commercializing vaccines for infectious diseases. It has manufacturing sites in Livingston, Scotland; Solna, Sweden and Vienna, Austria, with other offices in France, Canada and the United States.
Rhea-AI Summary

Valneva SE entered a senior term loan facility totaling $500.0M, split into a committed $215.0M Tranche A expected to fund around Oct 17, 2025 and up to $285.0M of uncommitted subsequent tranches available with lender consent. Proceeds of Tranche A plus cash on hand will repay an existing credit agreement in full; subsequent tranches are reserved for general corporate and working capital needs.

The Term Loans mature five years after each funding date, carry a fixed interest rate of 9.00% per annum with quarterly payments, and include an upfront fee of 2.00% of principal at each funding. Prepayments are permitted but subject to a premium up to 3.00% depending on timing. Separately, the company reconfirmed its Phase 3 Lyme vaccine trial remains on track, with Pfizer targeting BLA and MAA submissions in 2026, VALOR trial outcomes expected in H1 2026, and a contemplated launch in H2 2027 pending approval.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
current report
-
Rhea-AI Summary

Valneva SE entered a senior term loan facility for an aggregate $500.0M, split into a $215.0M committed Tranche A (expected funded ~Oct 17, 2025) and up to $285.0M of uncommitted subsequent tranches subject to lender consent. Proceeds of Tranche A plus cash on hand will repay an existing credit agreement; subsequent tranches are designated for general corporate and working capital including business development and permitted acquisitions. The loans mature five years after each tranche funding and carry a fixed interest rate of 9.00% with quarterly payments. There is a funding fee equal to 2.00% of principal and prepayment premiums of 3.00% if repaid before the third anniversary and 2.00% thereafter. Separately, Valneva reconfirms its Phase 3 Lyme vaccine trial remains on track; Pfizer targets BLA and MAA submissions in 2026 if data are positive, with VALOR outcomes expected in H1 2026 and a potential Pfizer launch in H2 2027.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
current report
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
current report
Rhea-AI Summary

Bpifrance Participations, EPIC Bpifrance, Bpifrance S.A., Caisse des de9pf4ts et consignations (CDC) and CDC Croissance filed Amendment No. 3 to their Schedule 13D reporting positions in Valneva SE ordinary shares.

The filing shows Bpifrance Participations directly holds 8,639,886 ordinary shares and 17,259,364 voting rights; CDC Croissance holds 4,550,812 ordinary shares and voting rights. Aggregate voting rights reported for certain Reporting Persons are higher due to indirect holdings and joint ownership structures, with CDC reported as holding 21,810,176 voting rights. The percentages are calculated on 171,730,534 ordinary shares outstanding and 187,854,877 voting rights under U.S. law, producing a 9.2% voting-rights stake for Bpifrance Participations and an 11.6% voting-rights stake for CDC.

The Reporting Persons state the shares were acquired for investment purposes and that the apparent reduction in their percentage ownership results solely from an increase in outstanding shares, not from sales by the Reporting Persons. No reportable transactions occurred in the last 60 days and no plans currently exist for the corporate actions listed in Schedule 13D instructions, though they reserve the right to change investment intent.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
other
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
current report
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
current report
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
current report
-
Rhea-AI Summary

Valneva reported consolidated revenues of €97.6 million for the six months ended June 30, 2025, with product sales rising to €91.0 million from €68.3 million a year earlier. Improved manufacturing performance lifted the product gross margin (excluding IXCHIQ) to 59.2%, supporting stronger cash generation despite a reported net loss of €20.8 million and an Adjusted EBITDA loss of €6.0 million. Cash and cash equivalents were €161.3 million.

Operationally, Valneva continued commercial rollouts and partnerships: IXCHIQ received marketing authorizations (including Brazil and the UK), a $32.8 million DoD supply contract for IXIARO was secured, an exclusive German distribution deal with CSL Seqirus was signed, and the VALOR Phase 3 Lyme trial completed full vaccination with Pfizer aiming for regulatory filings in 2026 subject to positive data. The company is advancing Shigella and Zika programs and expects to focus sales on proprietary vaccines while winding down third-party distribution.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
current report
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
current report
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
current report

FAQ

What is the current stock price of Valneva Se (VALN)?

The current stock price of Valneva Se (VALN) is $11.03 as of October 8, 2025.

What is the market cap of Valneva Se (VALN)?

The market cap of Valneva Se (VALN) is approximately 914.5M.
Valneva Se

Nasdaq:VALN

VALN Rankings

VALN Stock Data

914.47M
79.74M
5.57%
0.02%
Biotechnology
Healthcare
Link
France
Saint-Herblain